Abstract
The use of “omics” is increasing in research areas looking to identify biomarkers or early preclinical signs of disease or to increase understanding of complex pathological processes that determines prognosis of the disease. Diabetic kidney disease is no exception as it is an area in need of further improvement of both understanding and prognosis. In addition, there is a notion that pretreatment investigations using techniques like proteomics, lipidomics and metabolomics can help individualize therapy thus fulfilling the wish for personalized medicine. An increasing number of cohort studies using these techniques are published, but only few have been validated in external cohorts or even replicated by other groups. In essence, to achieve clinical impact and usefulness, prospective validation is needed. So far, only the urinary proteomics based PRIORITY study has tried to do this, as discussed in this review. Other areas are promising, but are currently lacking such efforts. In this review we report and discuss the current status of urinary proteomics as well as plasma metabolomics and lipidomics with an overview of the results so far, and with some comments and perspectives regarding future developments and implementation. As is evident, these techniques are promising, but there is still some way before widespread clinical use can be foreseen.
Similar content being viewed by others
References
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B (2018) IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 138:271–281
Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L (2014) Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 370(16):1514–1523
Persson F, Rossing P (2018) Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl (2011) 8(1):2–7
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD et al (2014) Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 37(10):2864–2883
Bjerg L, Hulman A, Carstensen B, Charles M, Witte DR, Jorgensen ME (2019) Effect of duration and burden of microvascular complications on mortality rate in type 1 diabetes: an observational clinical cohort study. Diabetologia 62:633–643
Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH (2013) Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol 24(2):302–308
Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease. The Framingham study. JAMA 241(19):2035–2038
Hayes A, Arima H, Woodward M, Chalmers J, Poulter N, Hamet P, Clarke P (2016) Changes in quality of life associated with complications of diabetes: results from the ADVANCE Study. Value Health 19(1):36–41
Li R, Bilik D, Brown MB, Zhang P, Ettner SL, Ackermann RT, Crosson JC, Herman WH (2013) Medical costs associated with type 2 diabetes complications and comorbidities. Am J Manag Care 19(5):421–430
Vupputuri S, Kimes TM, Calloway MO, Christian JB, Bruhn D, Martin AA, Nichols GA (2014) The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complicat 28(1):10–16
Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, Doria A, Warram JH (2014) Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 37(1):226–234
Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E et al (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21(4):556–563
Fiorentino M, Bolignano D, Tesar V, Pisano A, Biesen WV, Tripepi G, D’Arrigo G, Gesualdo L (2017) Group E-EIW: renal biopsy in patients with diabetes: a pooled meta-analysis of 48 studies. Nephrol Dial Transpl 32(1):97–110
Parving HH, Persson F, Rossing P (2015) Microalbuminuria: a parameter that has changed diabetes care. Diabetes Res Clin Pract 107(1):1–8
Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki CM, Herman WH (2001) Does microalbuminuria predict diabetic nephropathy? Diabetes Care 24(9):1560–1566
Chen C, Wang C, Hu C, Han Y, Zhao L, Zhu X, Xiao L, Sun L (2017) Normoalbuminuric diabetic kidney disease. Front Med 11(3):310–318
Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM et al (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63(4):1499–1507
National Kidney F (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886
Gaede P, Vedel P, Parving HH, Pedersen O (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353(9153):617–622
The Diabetes Control and Complications (DCCT) Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 47(6):1703–1720
UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352(9131):854–865
UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352(9131):837–853
Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, Cuddihy R, Cushman WC, Genuth S, Grimm RH Jr et al (2010) Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 376(9739):419–430
Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323–334
Mann JFE, Orsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, Tornoe K, Zinman B, Buse JB, Committee LS et al (2017) Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med 377(9):839–848
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834–1844
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644–657
Muskiet MHA, Tonneijck L, Huang Y, Liu M, Saremi A, Heerspink HJL, van Raalte DH (2018) Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 6(11):859–869
Jardine MJ, Mahaffey KW, Neal B, Agarwal R, Bakris GL, Brenner BM, Bull S, Cannon CP, Charytan DM, de Zeeuw D et al (2017) The canagliflozin and renal endpoints in diabetes with established nephropathy clinical evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 46(6):462–472
Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306
Bauer JH, Reams GP, Hewett J, Klachko D, Lau A, Messina C, Knaus V (1992) A randomized, double-blind, placebo-controlled trial to evaluate the effect of enalapril in patients with clinical diabetic nephropathy. Am J Kidney Dis 20(5):443–457
Bjorck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M (1986) Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. Br Med J (Clin Res Ed) 293(6545):471–474
Parving HH, Hommel E, Smidt UM (1988) Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy. BMJ 297(6656):1086–1091
Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y (1985) Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313(26):1617–1620
Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH (2005) Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 28(9):2106–2112
Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, Parving HH (2006) Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 70(3):536–542
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884–894
Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Nowack C, Kolkhof P, Ferreira AC, Schloemer P, Filippatos G et al (2019) Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol 50(5):333–344
Heerspink HJL, Andress DL, Bakris G, Brennan JJ, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray J et al (2018) Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab 20(8):1829–1835
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV et al (2019) Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 393:1937–1947
Hyotylainen T, Oresic M (2014) Systems biology strategies to study lipidomes in health and disease. Prog Lipid Res 55:43–60
Oresic M, Vidal-Puig A, Hanninen V (2006) Metabolomic approaches to phenotype characterization and applications to complex diseases. Expert Rev Mol Diagn 6(4):575–585
Kim K, Mall C, Taylor SL, Hitchcock S, Zhang C, Wettersten HI, Jones AD, Chapman A, Weiss RH (2014) Mealtime, temporal, and daily variability of the human urinary and plasma metabolomes in a tightly controlled environment. PLoS ONE 9(1):e86223
Holmes E, Li JV, Marchesi JR, Nicholson JK (2012) Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab 16(5):559–564
Hyotylainen T, Oresic M (2015) Analytical lipidomics in metabolic and clinical research. Trends Endocrinol Metab 26(12):671–673
Mischak H, Ioannidis JP, Argiles A, Attwood TK, Bongcam-Rudloff E, Broenstrup M, Charonis A, Chrousos GP, Delles C, Dominiczak A et al (2012) Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42(9):1027–1036
Davies R (2018) The metabolomic quest for a biomarker in chronic kidney disease. Clin Kidney J 11(5):694–703
Zhao YY, Vaziri ND, Lin RC (2015) Lipidomics: new insight into kidney disease. Adv Clin Chem 68:153–175
Persson F, Rossing P (2019) Urinary proteomics and precision medicine for chronic kidney disease: current status and future perspectives. Proteomics Clin Appl 13:e1800176
Mulder S, Hamidi H, Kretzler M, Ju W (2018) An integrative systems biology approach for precision medicine in diabetic kidney disease. Diabetes Obes Metab 20(Suppl 3):6–13
Holmes MV, Ala-Korpela M, Smith GD (2017) Mendelian randomization in cardiometabolic disease: challenges in evaluating causality. Nat Rev Cardiol 14(10):577–590
Nassar AF, Wu T, Nassar SF, Wisnewski AV (2017) UPLC-MS for metabolomics: a giant step forward in support of pharmaceutical research. Drug Discov Today 22(2):463–470
Ramautar R, Somsen GW, de Jong GJ (2019) CE-MS for metabolomics: developments and applications in the period 2016-2018. Electrophoresis 40(1):165–179
Soininen P, Kangas AJ, Wurtz P, Suna T, Ala-Korpela M (2015) Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. Circ Cardiovasc Genet 8(1):192–206
Soininen P, Kangas AJ, Wurtz P, Tukiainen T, Tynkkynen T, Laatikainen R, Jarvelin MR, Kahonen M, Lehtimaki T, Viikari J et al (2009) High-throughput serum NMR metabonomics for cost-effective holistic studies on systemic metabolism. Analyst 134(9):1781–1785
Ibarra-Gonzalez I, Cruz-Bautista I, Bello-Chavolla OY, Vela-Amieva M, Pallares-Mendez R, Ruiz de Santiago YND, Salas-Tapia MF, Rosas-Flota X, Gonzalez-Acevedo M, Palacios-Penaloza A et al (2018) Optimization of kidney dysfunction prediction in diabetic kidney disease using targeted metabolomics. Acta Diabetol 55(11):1151–1161
Good DM, Zurbig P, Argiles A, Bauer HW, Behrens G, Coon JJ, Dakna M, Decramer S, Delles C, Dominiczak AF et al (2010) Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 9(11):2424–2437
Mischak H (2015) Pro: urine proteomics as a liquid kidney biopsy: no more kidney punctures! Nephrol Dial Transpl 30(4):532–537
Magalhaes P, Pejchinovski M, Markoska K, Banasik M, Klinger M, Svec-Billa D, Rychlik I, Rroji M, Restivo A, Capasso G et al (2017) Association of kidney fibrosis with urinary peptides: a path towards non-invasive liquid biopsies? Sci Rep 7(1):16915
Argiles A, Siwy J, Duranton F, Gayrard N, Dakna M, Lundin U, Osaba L, Delles C, Mourad G, Weinberger KM et al (2013) CKD273, a new proteomics classifier assessing CKD and its prognosis. PLoS ONE 8(5):e62837
Gu YM, Thijs L, Liu YP, Zhang Z, Jacobs L, Koeck T, Zurbig P, Lichtinghagen R, Brand K, Kuznetsova T et al (2014) The urinary proteome as correlate and predictor of renal function in a population study. Nephrol Dial Transpl 29(12):2260–2268
Schanstra JP, Zurbig P, Alkhalaf A, Argiles A, Bakker SJ, Beige J, Bilo HJ, Chatzikyrkou C, Dakna M, Dawson J et al (2015) Diagnosis and prediction of CKD progression by assessment of urinary peptides. J Am Soc Nephrol 26(8):1999–2010
Zurbig P, Jerums G, Hovind P, Macisaac RJ, Mischak H, Nielsen SE, Panagiotopoulos S, Persson F, Rossing P (2012) Urinary proteomics for early diagnosis in diabetic nephropathy. Diabetes 61(12):3304–3313
Siwy J, Schanstra JP, Argiles A, Bakker SJ, Beige J, Boucek P, Brand K, Delles C, Duranton F, Fernandez-Fernandez B et al (2014) Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy. Nephrol Dial Transpl 29(8):1563–1570
Roscioni SS, de Zeeuw D, Hellemons ME, Mischak H, Zurbig P, Bakker SJ, Gansevoort RT, Reinhard H, Persson F, Lajer M et al (2013) A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus. Diabetologia 56(2):259–267
Pontillo C, Jacobs L, Staessen JA, Schanstra JP, Rossing P, Heerspink HJL, Siwy J, Mullen W, Vlahou A, Mischak H et al (2017) A urinary proteome-based classifier for the early detection of decline in glomerular filtration. Nephrol Dial Transpl 32(9):1510–1516
Lindhardt M, Persson F, Zurbig P, Stalmach A, Mischak H, de Zeeuw D, Lambers Heerspink H, Klein R, Orchard T, Porta M et al (2017) Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study. Nephrol Dial Transpl 32(11):1866–1873
Pontillo C, Zhang ZY, Schanstra JP, Jacobs L, Zurbig P, Thijs L, Ramirez-Torres A, Heerspink HJL, Lindhardt M, Klein R et al (2017) Prediction of chronic kidney disease stage 3 by CKD273, a urinary proteomic biomarker. Kidney Int Rep 2(6):1066–1075
Lindhardt M, Persson F, Currie G, Pontillo C, Beige J, Delles C, von der Leyen H, Mischak H, Navis G, Noutsou M et al (2016) Proteomic prediction and renin angiotensin aldosterone system Inhibition prevention of early diabetic nephRopathy in TYpe 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial. BMJ Open 6(3):e010310
Tofte N, Lindhardt M, Adamova K, Bakker SJL, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I et al (2020) Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial. Lancet Diabetes Endocrinol 8(4):301–312
Sekula P, Goek ON, Quaye L, Barrios C, Levey AS, Romisch-Margl W, Menni C, Yet I, Gieger C, Inker LA et al (2016) A metabolome-wide association study of kidney function and disease in the general population. J Am Soc Nephrol 27(4):1175–1188
Sharma K, Karl B, Mathew AV, Gangoiti JA, Wassel CL, Saito R, Pu M, Sharma S, You YH, Wang L et al (2013) Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 24(11):1901–1912
Makinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, Groop PH, Ala-Korpela M, FinnDiane Study G (2006) Diagnosing diabetic nephropathy by 1H NMR metabonomics of serum. MAGMA 19(6):281–296
Makinen VP, Tynkkynen T, Soininen P, Forsblom C, Peltola T, Kangas AJ, Groop PH, Ala-Korpela M (2012) Sphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study). Metabolomics 8(3):369–375
Tofte N, Vogelzangs N, Mook-Kanamori D, Brahimaj A, Nano J, Ahmadizar F, Willems van Dijk K, Frimodt-Moller M, Arts I, Beulens JWJ et al (2020) Plasma metabolomics identifies markers of impaired renal function: a meta-analysis of 3,089 persons with type 2 diabetes. J Clin Endocrinol Metab 105(7):dgaa173. https://doi.org/10.1210/clinem/dgaa173
Makinen VP, Soininen P, Forsblom C, Parkkonen M, Ingman P, Kaski K, Groop PH, Ala-Korpela M, FinnDiane Study G (2008) 1H NMR metabonomics approach to the disease continuum of diabetic complications and premature death. Mol Syst Biol 4:167
Makinen VP, Soininen P, Kangas AJ, Forsblom C, Tolonen N, Thorn LM, Viikari J, Raitakari OT, Savolainen M, Groop PH et al (2013) Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med 273(4):383–395
Makinen VP, Tynkkynen T, Soininen P, Peltola T, Kangas AJ, Forsblom C, Thorn LM, Kaski K, Laatikainen R, Ala-Korpela M et al (2012) Metabolic diversity of progressive kidney disease in 325 patients with type 1 diabetes (the FinnDiane Study). J Proteome Res 11(3):1782–1790
Barrios C, Zierer J, Wurtz P, Haller T, Metspalu A, Gieger C, Thorand B, Meisinger C, Waldenberger M, Raitakari O et al (2018) Circulating metabolic biomarkers of renal function in diabetic and non-diabetic populations. Sci Rep 8(1):15249
Welsh P, Rankin N, Li Q, Mark PB, Wurtz P, Ala-Korpela M, Marre M, Poulter N, Hamet P, Chalmers J et al (2018) Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia 61(7):1581–1591
Liu JJ, Ghosh S, Kovalik JP, Ching J, Choi HW, Tavintharan S, Ong CN, Sum CF, Summers SA, Tai ES et al (2017) Profiling of plasma metabolites suggests altered mitochondrial fuel usage and remodeling of sphingolipid metabolism in individuals with type 2 diabetes and kidney disease. Kidney Int Rep 2(3):470–480
Han LD, Xia JF, Liang QL, Wang Y, Wang YM, Hu P, Li P, Luo GA (2011) Plasma esterified and non-esterified fatty acids metabolic profiling using gas chromatography-mass spectrometry and its application in the study of diabetic mellitus and diabetic nephropathy. Anal Chim Acta 689(1):85–91
Hirayama A, Nakashima E, Sugimoto M, Akiyama S, Sato W, Maruyama S, Matsuo S, Tomita M, Yuzawa Y, Soga T (2012) Metabolic profiling reveals new serum biomarkers for differentiating diabetic nephropathy. Anal Bioanal Chem 404(10):3101–3109
Zhu C, Liang QL, Hu P, Wang YM, Luo GA (2011) Phospholipidomic identification of potential plasma biomarkers associated with type 2 diabetes mellitus and diabetic nephropathy. Talanta 85(4):1711–1720
Haukka JK, Sandholm N, Forsblom C, Cobb JE, Groop PH, Ferrannini E (2018) Metabolomic profile predicts development of microalbuminuria in individuals with type 1 diabetes. Sci Rep 8(1):13853
Klein RL, Hammad SM, Baker NL, Hunt KJ, Al Gadban MM, Cleary PA, Virella G, Lopes-Virella MF, Group DER (2014) Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism 63(10):1287–1295
Niewczas MA, Mathew AV, Croall S, Byun J, Major M, Sabisetti VS, Smiles A, Bonventre JV, Pennathur S, Krolewski AS (2017) Circulating modified metabolites and a risk of ESRD in patients with type 1 diabetes and chronic kidney disease. Diabetes Care 40(3):383–390
Pena MJ, Lambers Heerspink HJ, Hellemons ME, Friedrich T, Dallmann G, Lajer M, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D et al (2014) Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with type 2 diabetes mellitus. Diabet Med 31:1138–1147
Solini A, Manca ML, Penno G, Pugliese G, Cobb JE, Ferrannini E (2016) Prediction of declining renal function and albuminuria in patients with type 2 diabetes by metabolomics. J Clin Endocrinol Metab 101(2):696–704
Niewczas MA, Sirich TL, Mathew AV, Skupien J, Mohney RP, Warram JH, Smiles A, Huang X, Walker W, Byun J et al (2014) Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney Int 85(5):1214–1224
Hu JR, Coresh J, Inker LA, Levey AS, Zheng Z, Rebholz CM, Tin A, Appel LJ, Chen J, Sarnak MJ et al (2018) Serum metabolites are associated with all-cause mortality in chronic kidney disease. Kidney Int 94(2):381–389
Afshinnia F, Rajendiran TM, Karnovsky A, Soni T, Wang X, Xie D, Yang W, Shafi T, Weir MR, He J et al (2016) Lipidomic signature of progression of chronic kidney disease in the chronic renal insufficiency cohort. Kidney Int Rep 1(4):256–268
Luo S, Coresh J, Tin A, Rebholz CM, Appel LJ, Chen J, Vasan RS, Anderson AH, Feldman HI, Kimmel PL et al (2019) Serum metabolomic alterations associated with proteinuria in CKD. Clin J Am Soc Nephrol 13:342–353
Tofte N, Suvitaival T, Trost K, Mattila IM, Theilade S, Winther SA, Ahluwalia TS, Frimodt-Moller M, Legido-Quigley C, Rossing P (2019) Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes. Front Endocrinol (Lausanne) 10:818
Tofte N, Suvitaival T, Ahonen L, Winther SA, Theilade S, Frimodt-Moller M, Ahluwalia TS, Rossing P (2019) Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes. Sci Rep 9(1):16398
Rodriguez-Ortiz ME, Pontillo C, Rodriguez M, Zurbig P, Mischak H, Ortiz A (2018) Novel urinary biomarkers for improved prediction of progressive EGFR loss in early chronic kidney disease stages and in high risk individuals without chronic kidney disease. Sci Rep 8(1):15940
Chen L, Cheng CY, Choi H, Ikram MK, Sabanayagam C, Tan GS, Tian D, Zhang L, Venkatesan G, Tai ES et al (2016) Plasma metabonomic profiling of diabetic retinopathy. Diabetes 65(4):1099–1108
Canfora EE, Jocken JW, Blaak EE (2015) Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 11(10):577–591
Lassenius MI, Fogarty CL, Blaut M, Haimila K, Riittinen L, Paju A, Kirveskari J, Jarvela J, Ahola AJ, Gordin D et al (2017) Intestinal alkaline phosphatase at the crossroad of intestinal health and disease—a putative role in type 1 diabetes. J Intern Med 281(6):586–600
Herman-Edelstein M, Scherzer P, Tobar A, Levi M, Gafter U (2014) Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J Lipid Res 55(3):561–572
Kang HM, Ahn SH, Choi P, Ko YA, Han SH, Chinga F, Park AS, Tao J, Sharma K, Pullman J et al (2015) Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development. Nat Med 21(1):37–46
Rossing K, Mischak H, Parving HH, Christensen PK, Walden M, Hillmann M, Kaiser T (2005) Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney Int 68(1):193–205
Andersen S, Mischak H, Zurbig P, Parving HH, Rossing P (2010) Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 11:29
Niewczas MA, Pavkov ME, Skupien J, Smiles A, Md Dom ZI, Wilson JM, Park J, Nair V, Schlafly A, Saulnier PJ et al (2019) A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat Med 25(5):805–813
Lehto M, Groop PH (2018) The gut-kidney axis: putative interconnections between gastrointestinal and renal disorders. Front Endocrinol (Lausanne) 9:553
Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q, Lin J, Bierhaus A, Nawroth P, Hannak D et al (2003) Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 9(3):294–299
Babaei-Jadidi R, Karachalias N, Ahmed N, Battah S, Thornalley PJ (2003) Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine. Diabetes 52(8):2110–2120
Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ et al (2010) A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 33(7):1598–1601
Raval AD, Thakker D, Rangoonwala AN, Gor D, Walia R (2015) Vitamin B and its derivatives for diabetic kidney disease. Cochrane Database Syst Rev 1:CD009403
Tuttle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW (2005) The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28(11):2686–2690
Iso K, Tada H, Kuboki K, Inokuchi T (2001) Long-term effect of epalrestat, an aldose reductase inhibitor, on the development of incipient diabetic nephropathy in Type 2 diabetic patients. J Diabetes Complicat 15(5):241–244
Critselis E, Vlahou A, Stel VS, Morton RL (2017) Cost-effectiveness of screening type 2 diabetes patients for chronic kidney disease progression with the CKD273 urinary peptide classifier as compared to urinary albumin excretion. Nephrol Dial Transpl 33:441–449
Persson F, Lindhardt M, Rossing P, Parving HH (2016) Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: a systematic review. J Renin Angiotensin Aldosterone Syst 17(3)
Cherney D, Perkins BA, Lytvyn Y, Heerspink H, Rodriguez-Ortiz ME, Mischak H (2017) The effect of sodium/glucose cotransporter 2 (SGLT2) inhibition on the urinary proteome. PLoS One 12(10):e0186910. https://doi.org/10.1371/journal.pone.0186910.eCollection2017
Pena MJ, Lambers Heerspink HJ, Hellemons ME, Friedrich T, Dallmann G, Lajer M, Bakker SJ, Gansevoort RT, Rossing P, de Zeeuw D et al (2014) Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus. Diabetic Med: J Br Diabetic Assoc 31(9):1138–1147
Acknowledgements
This work was supported by the Novo Nordisk Foundation (grant number NNF14OC0013659 PROTON Personalising treatment of diabetic kidney disease.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
P.R. is on the Steering Committee of the following clinical trials: CADA-DIA (Bayer), Fidelio (Bayer) Figaro (Bayer), DAPA-CKD (Astra Zeneca), and FLOW (Novo-Nordisk); The Steno Diabetes Center Copenhagen has received fees for consultancy and/or speaking from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Eli Lilly, Mundi, Novo Nordisk and Sanofi Aventis. F.P. has served as a consultant, on advisory boards or as an educator for Astra Zeneca, Novo Nordisk, Sanofi, Mundipharma, MSD, Boehringer Ingelheim, Novartis, and Amgen, and has received research grants to the Steno Diabetes Center Copenhagen from Novo Nordisk, Amgen, and Astra Zeneca N.T. declares no conflicts.
Ethical standards
There are no ethical issues related to this review as it only includes previously published papers.
Research involving human Participants and/or animals
This is a review so no participants or animals were investigated.
Informed consent
Not relevant as this is a review and no participants were investigated.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tofte, N., Persson, F. & Rossing, P. Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?. J Nephrol 33, 931–948 (2020). https://doi.org/10.1007/s40620-020-00759-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40620-020-00759-4